US 12,410,222 B2
Fusokines involving cytokines with strongly reduced receptor binding affinities
Jan Tavernier, Balegem (BE); Jennyfer Bultinck, Ledeberg (BE); Sarah Gerlo, Ghent (BE); Gilles Uze, Montpellier (FR); Franciane Paul, Montpellier (FR); and Yann Bordat, Montpellier (FR)
Assigned to VIB VZW, Ghent (BE); Universiteit Gent, Ghent (BE); Centre National De Le Recherche Scientifque, Paris (FR); Universitè De Montpellier, Montpellier (FR); and Centre Hospitalier Regional Universitaire de Montpellier, Montpellier (FR)
Filed by VIB VZW, Ghent (BE); Universiteit Gent, Ghent (BE); Centre National De Le Recherche Scientifique, Paris (FR); Université De Montpellier, Montpellier (FR); and Centre Hospitalier Regional Universitaire de Montpellier, Montpellier (FR)
Filed on Apr. 29, 2022, as Appl. No. 17/733,026.
Application 16/103,302 is a division of application No. 14/905,343, granted, now 10,640,542, issued on May 5, 2020, previously published as PCT/EP2014/064227, filed on Jul. 3, 2014.
Application 17/733,026 is a continuation of application No. 16/103,302, filed on Aug. 14, 2018, granted, now 11,358,997.
Claims priority of application No. 13306034 (EP), filed on Jul. 18, 2013.
Prior Publication US 2023/0054612 A1, Feb. 23, 2023
Int. Cl. C07K 14/52 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/22 (2006.01); A61P 37/04 (2006.01); C07K 14/525 (2006.01); C07K 14/545 (2006.01); C07K 14/56 (2006.01); C07K 14/575 (2006.01)
CPC C07K 14/521 (2013.01) [A61K 38/195 (2013.01); A61K 38/2006 (2013.01); A61P 37/04 (2018.01); C07K 14/52 (2013.01); C07K 14/523 (2013.01); C07K 14/525 (2013.01); C07K 14/545 (2013.01); C07K 14/56 (2013.01); C07K 14/5759 (2013.01); A61K 38/19 (2013.01); A61K 38/2264 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01)] 2 Claims
 
1. A composition comprising a fusion protein comprising at least two cytokines, wherein the cytokines are single chain tumor necrosis factor alpha (scTNFα) and mutant leptin and wherein leptin comprises a mutation selected from L86S and L86N that reduces binding activity of leptin to its receptor as compared to wild type leptin and scTNFα is wild-type and provides cell-specific targeting that restores activity of the mutant leptin on the targeted cells.